MA52569B1 - Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendant - Google Patents
Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendantInfo
- Publication number
- MA52569B1 MA52569B1 MA52569A MA52569A MA52569B1 MA 52569 B1 MA52569 B1 MA 52569B1 MA 52569 A MA52569 A MA 52569A MA 52569 A MA52569 A MA 52569A MA 52569 B1 MA52569 B1 MA 52569B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- voltage
- potassium channel
- bioavailability
- exposure
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000004036 potassium channel stimulating agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000004257 Potassium Channel Human genes 0.000 abstract 1
- 229940125516 allosteric modulator Drugs 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- FJNPZKZPWVVSON-UHFFFAOYSA-N n-[4-(6-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CC=C(F)C=C3CC2)=C1 FJNPZKZPWVVSON-UHFFFAOYSA-N 0.000 abstract 1
- 108020001213 potassium channel Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Selon certains modes de réalisation, la présente invention concerne des procédés et des utilisations pour traiter des troubles épileptiques chez un être humain, les procédés et les utilisations comprenant l'administration par voie orale d'une quantité thérapeutiquement efficace du modulateur allostérique du canal potassique sensible à la tension, n-[4-(6-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-2,6-diméthylphényl]-3,3- diméthylbutanamide (composé a), à l'homme en ayant besoin, par exemple, dans des conditions d'alimentation. La présente invention concerne en outre divers procédés améliorés de thérapie et d'administration du composé a.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670253P | 2018-05-11 | 2018-05-11 | |
| PCT/US2019/031872 WO2019217924A1 (fr) | 2018-05-11 | 2019-05-10 | Procédés d'amélioration de la biodisponibilité et de l'exposition d'un dispositif d'ouverture de canal potassique sensible à la tension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA52569A MA52569A (fr) | 2021-03-17 |
| MA52569B1 true MA52569B1 (fr) | 2023-11-30 |
Family
ID=66669101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA52569A MA52569B1 (fr) | 2018-05-11 | 2019-05-10 | Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendant |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US11135214B2 (fr) |
| EP (2) | EP4279133A3 (fr) |
| JP (1) | JP2021523130A (fr) |
| KR (1) | KR20210020892A (fr) |
| CN (1) | CN112384216A (fr) |
| AU (1) | AU2019265002B2 (fr) |
| BR (1) | BR112020022713A2 (fr) |
| CA (1) | CA3099292A1 (fr) |
| CL (1) | CL2020002932A1 (fr) |
| CO (1) | CO2020015476A2 (fr) |
| CR (1) | CR20200602A (fr) |
| DK (1) | DK3790548T3 (fr) |
| EA (1) | EA202092720A1 (fr) |
| ES (1) | ES2964409T3 (fr) |
| FI (1) | FI3790548T3 (fr) |
| GE (1) | GEP20237527B (fr) |
| HR (1) | HRP20231447T1 (fr) |
| HU (1) | HUE064326T2 (fr) |
| LT (1) | LT3790548T (fr) |
| MA (1) | MA52569B1 (fr) |
| MD (1) | MD3790548T2 (fr) |
| MX (2) | MX2020012008A (fr) |
| PE (1) | PE20211211A1 (fr) |
| PH (1) | PH12020551898A1 (fr) |
| PL (1) | PL3790548T3 (fr) |
| PT (1) | PT3790548T (fr) |
| RS (1) | RS64922B1 (fr) |
| SG (1) | SG11202011102TA (fr) |
| SI (1) | SI3790548T1 (fr) |
| UA (1) | UA127229C2 (fr) |
| WO (1) | WO2019217924A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4279133A3 (fr) | 2018-05-11 | 2024-02-21 | Xenon Pharmaceuticals Inc. | Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendant |
| TW202128627A (zh) | 2019-10-10 | 2021-08-01 | 加拿大商再諾製藥公司 | 選擇性鉀通道調節劑之固態晶型 |
| KR20220113411A (ko) * | 2019-12-06 | 2022-08-12 | 제논 파마슈티칼스 인크. | KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도 |
| US20220288057A1 (en) * | 2021-02-09 | 2022-09-15 | Xenon Pharmaceuticals Inc. | Conjoint therapy for treating seizure disorders |
| CN116847843A (zh) * | 2021-02-09 | 2023-10-03 | 泽农医药公司 | 用于治疗快感缺乏的电压门控的钾通道开放剂 |
| CN113698345B (zh) * | 2021-10-27 | 2022-02-01 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的化合物及其制备和应用 |
| CA3151863C (fr) * | 2021-10-27 | 2024-01-02 | Shanghai Zhimeng Biopharma, Inc. | Compose comme regulateur de canal de potassium et preparation et utilisation connexes |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8236861B2 (en) | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
| WO2006130686A2 (fr) | 2005-06-02 | 2006-12-07 | Schering Corporation | Administration d'inhibiteurs de protease du vhc en combinaison avec des aliments pour ameliorer la biodisponibilite |
| US20090318507A2 (en) | 2006-05-02 | 2009-12-24 | Chris Rundfeldt | Potassium Channel Activators for the Prevention and Treatment of Dystonia and Dystonia Like Symptoms |
| US8993593B2 (en) * | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
| AU2007288253B2 (en) * | 2006-08-23 | 2013-05-02 | Xenon Pharmaceuticals Inc. | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators |
| US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
| EP4279133A3 (fr) | 2018-05-11 | 2024-02-21 | Xenon Pharmaceuticals Inc. | Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendant |
-
2019
- 2019-05-10 EP EP23185386.2A patent/EP4279133A3/fr active Pending
- 2019-05-10 MX MX2020012008A patent/MX2020012008A/es unknown
- 2019-05-10 CA CA3099292A patent/CA3099292A1/fr active Pending
- 2019-05-10 PE PE2020001843A patent/PE20211211A1/es unknown
- 2019-05-10 ES ES19727216T patent/ES2964409T3/es active Active
- 2019-05-10 EA EA202092720A patent/EA202092720A1/ru unknown
- 2019-05-10 MA MA52569A patent/MA52569B1/fr unknown
- 2019-05-10 CR CR20200602A patent/CR20200602A/es unknown
- 2019-05-10 SI SI201930665T patent/SI3790548T1/sl unknown
- 2019-05-10 CN CN201980046273.0A patent/CN112384216A/zh active Pending
- 2019-05-10 FI FIEP19727216.4T patent/FI3790548T3/fi active
- 2019-05-10 RS RS20231089A patent/RS64922B1/sr unknown
- 2019-05-10 PT PT197272164T patent/PT3790548T/pt unknown
- 2019-05-10 HU HUE19727216A patent/HUE064326T2/hu unknown
- 2019-05-10 EP EP19727216.4A patent/EP3790548B1/fr active Active
- 2019-05-10 LT LTEPPCT/US2019/031872T patent/LT3790548T/lt unknown
- 2019-05-10 SG SG11202011102TA patent/SG11202011102TA/en unknown
- 2019-05-10 BR BR112020022713-7A patent/BR112020022713A2/pt unknown
- 2019-05-10 KR KR1020207035334A patent/KR20210020892A/ko unknown
- 2019-05-10 WO PCT/US2019/031872 patent/WO2019217924A1/fr active Application Filing
- 2019-05-10 UA UAA202007781A patent/UA127229C2/uk unknown
- 2019-05-10 DK DK19727216.4T patent/DK3790548T3/da active
- 2019-05-10 HR HRP20231447TT patent/HRP20231447T1/hr unknown
- 2019-05-10 GE GEAP201915508A patent/GEP20237527B/en unknown
- 2019-05-10 MD MDE20210233T patent/MD3790548T2/ro unknown
- 2019-05-10 PL PL19727216.4T patent/PL3790548T3/pl unknown
- 2019-05-10 AU AU2019265002A patent/AU2019265002B2/en active Active
- 2019-05-10 JP JP2020562201A patent/JP2021523130A/ja active Pending
- 2019-05-13 US US16/410,851 patent/US11135214B2/en active Active
-
2020
- 2020-11-09 PH PH12020551898A patent/PH12020551898A1/en unknown
- 2020-11-10 MX MX2023013247A patent/MX2023013247A/es unknown
- 2020-11-11 CL CL2020002932A patent/CL2020002932A1/es unknown
- 2020-12-11 CO CONC2020/0015476A patent/CO2020015476A2/es unknown
-
2021
- 2021-10-01 US US17/449,785 patent/US20220062266A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52569B1 (fr) | Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendant | |
| MA48051B1 (fr) | Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide | |
| NO20025601D0 (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
| MA34474B1 (fr) | Agonistes de gpr40 | |
| EA200801492A1 (ru) | Фармацевтическое применение замещенных амидов | |
| MA30526B1 (fr) | Inhibiteurs de prolyle hydroxylase | |
| ATE318267T1 (de) | Einige alkylendiamin-substituierte heterocyclen | |
| BR9810841A (pt) | Inibidores de metaloprotease alicìclicos | |
| MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
| EA200400953A1 (ru) | Замещённые пиридиноны в качестве модуляторов map-киназы p38 | |
| MA27908A1 (fr) | Agents therapeutiques utiles pour le traitement de la douleur | |
| EA200100958A1 (ru) | Производные 4,5-диарил-3(2h)-фуранона как ингибиторы циклооксигеназы-2 | |
| NO20042596L (no) | Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1 | |
| ME00276B (fr) | Forme posologique transdermique a fermeture inviolable | |
| CO5590918A2 (es) | Formulaciones | |
| NO962841D0 (no) | Anvendelse av 2-hydroksy-5-fenylazobenzosyrederivater som colon cancer kjemopreventativer og kjemoterapeutiske midler | |
| TR199900046T2 (xx) | Se�ici siklooksijenaz-2 inhibit�rleri olarak ikameli piridinler. | |
| HK1087702A1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
| IN2005KO00312A (fr) | ||
| MA32150B1 (fr) | Inhibiteurs heterocycliques de la stearoyl-coa desaturase | |
| TNSN06370A1 (fr) | Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale | |
| DK1664016T3 (da) | Terapeutiske midler, der er anvendelige til behandling af smerter | |
| MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
| DE69912930D1 (de) | Neue salzformn von (2e)-5-amino-5-methylhex-2-enolsäure n-methyl-n-((1r)-1-(methylcarbamoyl)-2-phruylrthyl) carbamoyl)-2-(2-naphtyl)ethyl)amid | |
| DK1284977T3 (da) | Thienodibenzoazulenforbindelser som tumornekrosefaktorhæmmere |